Cancer trials are getting harder to complete, suggesting a role for more powerful RWE, AI solutions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Clinical trials for oncology drugs are running into unique challenges as protocols become more complex and as the number of new investigational agents continues to outpace all other drugs, according to a recent study by Tufts University researchers.

The study, “Protocol complexity and patient enrollment intensity challenges in oncology trials,” was conducted by Zachary Smith, a senior research analyst at Tufts, and led by Kenneth Getz, professor and director of the Tufts Center for the Study of Drug Development.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Associate Editor
Table of Contents


Associate Editor